Delivery to
Select Location
Delivery to
Select Location
Get 15% off pharmacy supplies
Download Vezeeta App now , add promocode PH15 and get the widest coverage, real time order tracking and a hassle-free experience- all in one app
Download Now
Ciprofar 500 mg - 10 F.C. Tablets
Box
This page may not cover all the information mentioned in the attached pamphlet of the manufacturing company
Medical Description
Antibiotic, belongs to the Fluoroquinolone group used in the treatment of pneumonia, prostatitis, salmonella infection, shigella infection, urinary tract infection, surgical site infection, bacterial meningitis and diabetic foot infection.
Indication & Usage
-Pneumonia: Oral: 750 mg every 12 hours, IV: 400 mg every 8 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days.
-Prostatitis: Acute bacterial prostatitis: Oral: 500 mg every 12 hours, IV: 400 mg every 12 hours. Duration of therapy is 4 to 6 weeks.
-Salmonella gastrointestinal infection: Oral: 500 mg twice daily for 3 to 14. Note: Immunosuppressed patients (eg, patients with HIV and CD4 count <200 cells/mm3) require a longer duration of treatment (eg, weeks to months) and may require a higher dose (eg, 750 mg twice daily).
-Urinary tract infection: Cystitis: Oral: Immediate release: 250 mg every 12 hours, while the extended release: 500 mg every 24 hours, duration: 3 days females or 5 days for males. Complicated urinary tract infection, (including pyelonephritis): Oral: Immediate release: 500 mg every 12 hours for 5 to 7 days, while the extended release: 1 g every 24 hours for 5 to 7 days, IV (inpatient): 400 mg every 12 hours for a total of 5 to 7 days.
-Bacterial meningitis: IV: 400 mg every 8 to 12 hours, must be used in combination with other appropriate agents.
-Diabetic foot infection: Mild to moderate infection: Oral: 500 mg every 12 hours (750 mg every 12 hours if Pseudomonas aeruginosa is suspected), while in case of moderate to severe infection: IV: 400 mg every 12 hours (400 mg every 8 hours if P. aeruginosa is suspected).
-Chronic obstructive pulmonary disease: Oral: 500 to 750 mg twice daily for 5 to 7 days.
-Prophylaxis or treatment for bite wound infection (animal and human bites): Oral: 500 to 750 mg twice daily, IV: 400 mg every 12 hours, duration of therapy: 3 to 5 days for prophylaxis; duration of treatment for established infection is typically 5 to 14 days and varies based on patient-specific factors.
-Cholera: Oral: 1 g as a single dose.
-Pediatric dosing: See Dosage and administration section.
Active Ingredients
Ciprofloxacin
Recommended Doctors
Dosage & Administration
-In case of missed doses: Oral, immediate release: Administer as soon as possible if ≥6 hours until next scheduled dose, otherwise, wait until next scheduled dose; do not double doses to compensate for missed dose, while in case of extended release: Administer as soon as possible if ≥8 hours until next scheduled dose, otherwise, wait until next scheduled dose; do not double doses to compensate for missed dose.
-Administer by slow IV infusion over 60 minutes into a large vein.
-May administer with most foods to minimize GI upset; avoid antacid use; maintain proper hydration and urine output.
-Avoid concomitant administration with dairy products (eg, milk, yogurt) or calcium-fortified juices alone.
-Separate administration of ciprofloxacin and calcium >800 mg by at least 2 hours.
-Administer immediate-release ciprofloxacin at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc.
-Extended release tablet: Do not crush, split, or chew.
-Pediatric dosing:
-In pediatric patients, ciprofloxacin is not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for some situations [eg, anthrax, resistance (cystic fibrosis)], General dosing for the susceptible infections: Infants, Children, and Adolescents: Mild to moderate infections: Oral, immediate release: 10 mg/kg/dose twice daily; maximum dose: 500 mg/dose, while for the severe infections: Oral, immediate release: 15 to 20 mg/kg/dose twice daily; maximum dose: 750 mg/dose, IV: 10 mg/kg/dose every 8 to 12 hours; maximum dose: 400 mg/dose.
Side Effects
-Aortic aneurysm, arthropathy, hepatotoxicity, peripheral neuropathy, phototoxicity/photoallergy, tendinopathy/tendon rupture and QT prolongation.
-Abdominal pain, diarrhea, dyspepsia, nausea, vomiting, vulvovaginal candidiasis, injection site reactions, dizziness, drowsiness, headache, insomnia, nervousness, restlessness, asthma, fever, acute myocardial infarction, angina pectoris, bradycardia, flushing, hypertension, hypotension, syncope, tachycardia, thrombophlebitis, vasculitis, vasodilation, diaphoresis, erythema multiforme, erythema nodosum, exfoliative dermatitis, maculopapular rash, phototoxicity, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vesicobullous dermatitis, xeroderma, albuminuria, gynecomastia, hyperglycemia, hypoglycemia, abdominal distress, anorexia, Clostridioides difficile colitis, constipation, dysgeusia, flatulence, gastrointestinal hemorrhage, intestinal obstruction, intestinal perforation, oral mucosa ulcer, pancreatitis, xerostomia, casts in urine, crystalluria, dysmenorrhea, hematuria, hemorrhagic cystitis, urinary frequency, vaginitis, agranulocytosis, petechia, prolonged prothrombin time, purpuric disease, cholestatic jaundice, hepatic necrosis, anaphylactic shock, anaphylaxis, angioedema, arthralgia, asthenia, joint stiffness, tremor, blurred vision, chromatopsia, decreased visual acuity, diplopia, nystagmus disorder, photopsia, hearing loss, tinnitus, acute kidney injury, bronchospasm, dyspnea, hemoptysis and laryngeal edema.
Safety Advice
-Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children.
-In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg: anthrax, multidrug resistant tuberculosis).
-Should not be given to patients suffering from hypersensitivity to ciprofloxacin.
-Prolonged use may result in fungal or bacterial superinfection.
-Use with caution in patients with renal impairment.
-Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.
-Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency.
-Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis so avoid ciprofloxacin in patients with known history of myasthenia gravis.
-Incase of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.
Storage
Store at room temperature.
Drug Interactions
-Blood glucose lowering medications: Quinolones may enhance the hypoglycemic effect of agents with blood glucose lowering effects.
-Antacids: May decrease the absorption of Quinolones.
-BCG Vaccine: Antibiotics may diminish the therapeutic effect of BCG Vaccine.
-Calcium Salts: May decrease the absorption of Quinolones.
-Cabamazepine: may increase the serum concentration of Carbamazepine.
-Corticosteroids: May enhance the adverse/toxic effect of Quinolones.
-Duloxetine: may increase the serum concentration of duloxetine.
-Magnesium Salts: May decrease the serum concentration of Quinolones.
-Methotrexate: Ciprofloxacin may increase the serum concentration of Methotrexate.
-Multivitamins/Minerals (containing vitamins ADEK, Folate, Iron): May decrease the serum concentration of Quinolones.
-Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones.
-Olanzapine: may increase the serum concentration of Olanzapine.
-Propranolol: may increase the serum concentration of Propranolol.
-Sildenafil: Ciprofloxacin may increase the serum concentration of Sildenafil.
-Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.
-Spironolactone: May enhance the arrhythmogenic effect of Ciprofloxacin.
-Sucralfate: May decrease the serum concentration of Quinolones.
-Theophylline Derivatives:may increase the serum concentration of Theophylline Derivatives.
-Tizanidine: Ciprofloxacin may increase the serum concentration of Tizanidine.
-Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists.
-Zinc Salts: May decrease the serum concentration of Quinolones.
Pregnancy & Lactation
-Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid. Alternative antibiotics are recommended in pregnant patients for indications such as meningococcal disease.
-Ciprofloxacin is present in breast milk. Ciprofloxacin is recommended for the prophylaxis and treatment of Bacillus anthracis in breastfeeding patients, based on adverse outcomes observed in animal studies, it is recommended that breastfeeding be discontinued during therapy and for 2 days after the last ciprofloxacin dose if used for indications other than treating maternal Bacillus anthracis.
Manufacture
PHARCO
Disclaimer
Show More
Delivery Address
Add Address
Are you sure you want to delete the address ?
Cancel
Delete